标题
Treatment of multiple sclerosis — success from bench to bedside
作者
关键词
-
出版物
Nature Reviews Neurology
Volume 15, Issue 1, Pages 53-58
出版商
Springer Nature
发表日期
2018-10-12
DOI
10.1038/s41582-018-0082-z
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis
- (2018) X. Montalban et al. EUROPEAN JOURNAL OF NEUROLOGY
- Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
- (2018) Raju Kapoor et al. LANCET NEUROLOGY
- ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
- (2018) Xavier Montalban et al. Multiple Sclerosis Journal
- Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis
- (2018) Mathias Granqvist et al. JAMA Neurology
- ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
- (2018) Xavier Montalban et al. Multiple Sclerosis Journal
- An Autopsy Case of Fulminant Hepatitis in a Patient with Multiple Sclerosis Treated by Interferon-Beta-1a
- (2017) Yuichi Yamazaki et al. INTERNAL MEDICINE
- Efficiency of antibody therapy in demyelinating diseases
- (2017) Tetsuya Akaishi et al. INTERNATIONAL IMMUNOLOGY
- Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases
- (2017) Robbert-Jan Gieselbach et al. JOURNAL OF NEUROLOGY
- Evolving concepts in the treatment of relapsing multiple sclerosis
- (2017) Giancarlo Comi et al. LANCET
- Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies
- (2017) Pei-Ran Ho et al. LANCET NEUROLOGY
- Oral Presentations
- (2017) Multiple Sclerosis Journal
- Late Breaking News Abstracts
- (2017) Multiple Sclerosis Journal
- Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets
- (2017) Nicola De Stefano et al. Multiple Sclerosis Journal
- Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study
- (2017) Gavin Giovannoni et al. Multiple Sclerosis Journal
- Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod
- (2017) Mahtab Ghadiri et al. Multiple Sclerosis Journal
- Treatment decisions in multiple sclerosis — insights from real-world observational studies
- (2017) Maria Trojano et al. Nature Reviews Neurology
- Alemtuzumab CARE-MS I 5-year follow-up
- (2017) Eva Havrdova et al. NEUROLOGY
- Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2017) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
- (2017) Xavier Montalban et al. NEW ENGLAND JOURNAL OF MEDICINE
- Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date
- (2017) Alberto Gajofatto Drug Design Development and Therapy
- Progressive Multifocal Leukoencephalopathy and Monoclonal Antibodies
- (2017) Chandrashekar Bohra et al. Cancer Control
- Oral Presentations
- (2017) Multiple Sclerosis Journal
- Late Breaking News Abstracts
- (2017) Multiple Sclerosis Journal
- Reduced brain atrophy rates are associated with lower risk of disability progression in patients with relapsing multiple sclerosis treated with cladribine tablets
- (2017) Nicola De Stefano et al. Multiple Sclerosis Journal
- Safety and efficacy of cladribine tablets in patients with relapsing–remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study
- (2017) Gavin Giovannoni et al. Multiple Sclerosis Journal
- Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod
- (2017) Mahtab Ghadiri et al. Multiple Sclerosis Journal
- Classifying PML risk with disease modifying therapies
- (2017) Joseph R. Berger Multiple Sclerosis and Related Disorders
- The role of natalizumab in the treatment of multiple sclerosis: benefits and risks
- (2017) Barry A. Singer Therapeutic Advances in Neurological Disorders
- Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis
- (2016) Robert J. Fox et al. Contemporary Clinical Trials
- Interferon-induced pulmonary hypertension
- (2016) Laurent Savale et al. CURRENT OPINION IN PULMONARY MEDICINE
- Acute pneumonitis and pericarditis related to alemtuzumab therapy in relapsing-remitting multiple sclerosis
- (2016) María Rosario Blasco et al. JOURNAL OF NEUROLOGY
- Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study
- (2016) Caryl J. Schwartzbach et al. JOURNAL OF NEUROLOGY
- Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
- (2016) Fred Lublin et al. LANCET
- Personalised medicine for multiple sclerosis care
- (2016) Arie Gafson et al. Multiple Sclerosis Journal
- Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy–NO
- (2016) Robert T Naismith Multiple Sclerosis Journal
- Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy–Commentary
- (2016) Aaron E Miller Multiple Sclerosis Journal
- Shared decision-making in multiple sclerosis
- (2016) Erica Colligan et al. Multiple Sclerosis Journal
- Dimethyl fumarate is coming of age
- (2016) Mar Tintoré et al. Nature Reviews Neurology
- Rituximab for treating multiple sclerosis
- (2016) Dennis Bourdette NEUROLOGY
- Personalised medicine for multiple sclerosis care
- (2016) Arie Gafson et al. Multiple Sclerosis Journal
- Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy–NO
- (2016) Robert T Naismith Multiple Sclerosis Journal
- Multiple sclerosis should be treated using a step-down strategy rather than a step-up strategy–Commentary
- (2016) Aaron E Miller Multiple Sclerosis Journal
- Shared decision-making in multiple sclerosis
- (2016) Erica Colligan et al. Multiple Sclerosis Journal
- Dimethyl fumarate in relapsing–remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety
- (2015) Duvyanshu Dubey et al. Expert Review of Neurotherapeutics
- Multiple sclerosis—a quiet revolution
- (2015) Richard M. Ransohoff et al. Nature Reviews Neurology
- Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis
- (2015) Jens Ingwersen et al. Neurotherapeutics
- Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis
- (2015) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dimethyl fumarate in relapsing–remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety
- (2015) Duvyanshu Dubey et al. Expert Review of Neurotherapeutics
- Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial
- (2014) Jeremy Chataway et al. LANCET
- Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial
- (2014) Gavin Giovannoni et al. LANCET NEUROLOGY
- Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2014) Aaron E Miller et al. LANCET NEUROLOGY
- Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study
- (2014) Peter A Calabresi et al. LANCET NEUROLOGY
- Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial
- (2014) Thomas P Leist et al. LANCET NEUROLOGY
- Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2014) Christian Confavreux et al. LANCET NEUROLOGY
- Significant clinical worsening after natalizumab withdrawal: Predictive factors
- (2014) A Vidal-Jordana et al. Multiple Sclerosis Journal
- Alemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis
- (2014) Hans-Peter Hartung et al. Multiple Sclerosis Journal
- Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis
- (2014) G. Karlsson et al. NEUROLOGY
- Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial
- (2014) J. Romme Christensen et al. NEUROLOGY
- Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis
- (2013) Omar Khan et al. ANNALS OF NEUROLOGY
- Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial
- (2013) Ralf Gold et al. LANCET
- Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial
- (2013) John Zajicek et al. LANCET NEUROLOGY
- Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial
- (2013) Patrick Vermersch et al. Multiple Sclerosis Journal
- Interferon for secondary progressive multiple sclerosis: a systematic review
- (2012) L. L. Mantia et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
- (2012) Jeffrey A Cohen et al. LANCET
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
- (2012) Alasdair J Coles et al. LANCET
- Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
- (2012) Robert J. Fox et al. NEW ENGLAND JOURNAL OF MEDICINE
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
- (2012) Ralf Gold et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study
- (2011) S Cook et al. Multiple Sclerosis Journal
- A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS
- (2011) M. S. Freedman et al. NEUROLOGY
- Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis
- (2011) P. W. O'Connor et al. NEUROLOGY
- Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
- (2011) Paul O'Connor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial
- (2010) Raju Kapoor et al. LANCET NEUROLOGY
- A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
- (2010) Gavin Giovannoni et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
- (2010) Jeffrey A. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
- (2009) Paul O'Connor et al. LANCET NEUROLOGY
- Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial
- (2008) Daniel D Mikol et al. LANCET NEUROLOGY
- B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
- (2008) Stephen L. Hauser et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started